NLR Ratio

NLR interpretation is significantly confounded in patients on corticosteroids. Prednisone 40 mg/day will cause neutrophilia (often raising ANC to 10–15 × 10³/µL from a baseline of 3–7 × 10³/µL) and lymphopenia (often reducing ALC to 0.5–1.0 × 10³/µL from a baseline of 1.5–3.0 × 10³/µL), yielding an NLR of 10–30 regardless of infection status. An NLR of 15 in a patient on high-dose steroids has no discriminatory value for infection. Alternative approaches: (1) Use absolute lymphocyte count alone — severe lymphopenia (<0.5 × 10³/µL) is associated with increased infection risk in immunocompromised hosts, independent of NLR. (2) Use CRP and procalcitonin as infection biomarkers that are less confounded by steroids (though steroids can also affect CRP). (3) Monitor the trend: if NLR was stable at 15 on steroids and suddenly jumps to 25–30, this might indicate a superimposed infection even in a steroid-treated patient. (4) Clinical assessment remains paramount — fever, new CXR infiltrate, positive cultures, and hemodynamic instability are more reliable than NLR in steroid-treated patients.

A single NLR of 7 is elevated above the normal range (2–4) but requires clinical context to determine significance. Isolated elevated NLR without clinical correlation can occur in many benign situations: morning blood draw (diurnal variation), recent vigorous exercise, physiologic stress from a painful procedure or exam, mild infection, recent vaccination, or early post-operative state. Ask: (1) Is there a clinical precipitant? Recent surgery? Active infection? Cancer diagnosis? (2) What are the absolute counts? ANC 7.0 + ALC 1.0 (NLR 7) is different from ANC 3.5 + ALC 0.5 (NLR 7) — the second pattern with lymphopenia is more concerning for immune dysfunction. (3) What was the NLR baseline? If the patient's previous NLR was 2.5 and it has risen to 7, this represents a significant change suggesting a new inflammatory process. (4) What is the clinical picture? In a cancer patient before immunotherapy, NLR 7 has significant prognostic implications. In a hospitalized patient with a post-op day 1 bowel resection, NLR 7 is expected SIRS and has little discriminatory value. Conclusion: a single NLR of 7 should prompt clinical evaluation and serial measurements rather than triggering immediate intervention. It should never be used in isolation for clinical decision-making.

There is no single validated NLR cutoff that applies universally across all diseases. Thresholds vary significantly by clinical context: **Sepsis/bacteremia:** NLR >5 is associated with bacteremia and organ dysfunction in multiple studies. NLR >10 is associated with severe sepsis and higher mortality. However, sensitivity and specificity at any single cutoff are modest (AUC ~0.7), and NLR should not be used alone to diagnose or rule out sepsis — it is an adjunct to clinical assessment and other biomarkers. **Cancer prognosis:** Disease-specific cutoffs (typically 3–5, varying by tumor type) — see tumor-type specific literature. Pre-immunotherapy: NLR >5 predicts poor ICI response in most studies. **COVID-19:** NLR >6 at admission predicts ICU requirement; NLR >20 suggests cytokine storm. **Cardiovascular disease:** NLR >3 is associated with adverse MACE in multiple studies. **Practical advice:** Use your institution's normal reference range as the baseline, identify the specific disease context you are applying NLR in, review the disease-specific literature for validated cutoffs, and always integrate NLR with the complete clinical picture. Avoid applying a single cutoff (e.g., 'NLR >5 = bad') across all diseases indiscriminately.

NLR can be calculated in children but requires age-specific reference ranges, as children have a lymphocyte-dominant CBC differential that is the reverse of adults. In the first few years of life, lymphocytes are the predominant WBC (ALC >ANC), resulting in NLR values <1, which would seem 'abnormal' by adult standards but are entirely physiologic. The lymphocyte/neutrophil predominance pattern gradually shifts to the adult neutrophil-dominant pattern around age 4–6 years. Age-specific NLR ranges: - Neonates: NLR <1 (lymphocyte predominant — normal) - Ages 1–4 years: NLR 0.5–1.5 (lymphocyte predominant) - Ages 5–10 years: NLR 1–2 (transitional) - Adolescents (age >12): approaching adult values (NLR 1–3) For pediatric NLR research, age-stratified reference ranges are essential. Adult NLR cutoffs should not be applied to young children. Pediatric oncology studies have investigated NLR in specific childhood cancers (neuroblastoma, ALL), but the evidence base is less robust than in adult solid tumors.